{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:01:11Z","timestamp":1761490871822,"version":"3.44.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001734","name":"University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006442","name":"Faculty of Health and Medical Sciences, University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Capital Region of Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009459","name":"Department of Infectious Diseases, Hvidovre University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009459","name":"Hvidovre University Hospital Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.virol.2019.09.014","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T13:24:09Z","timestamp":1569677049000},"page":"132-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent"],"prefix":"10.1016","volume":"540","author":[{"given":"Niels","family":"Mejer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2019.09.014_bib1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2019.09.014_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","article-title":"Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Beigel","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2019.09.014_bib3","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"Blight","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib4","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2019.09.014_bib5","doi-asserted-by":"crossref","first-page":"52471","DOI":"10.1074\/jbc.M308917200","article-title":"Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase","volume":"278","author":"Bougie","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2019.09.014_bib6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2019.09.014_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2893.2009.01109.x","article-title":"Evidence for action of ribavirin through the hepatitis C virus RNA polymerase","volume":"16","author":"Cannon","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virol.2019.09.014_bib8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s00018-005-5455-y","article-title":"The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus","volume":"63","author":"Dixit","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.virol.2019.09.014_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2019.09.014_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4939-8976-8_5","article-title":"Full-length open reading frame amplification of hepatitis C virus","volume":"1911","author":"Fahnoe","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.virol.2019.09.014_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.virol.2019.09.014_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.virol.2019.09.014_bib13","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/s41598-018-22620-2","article-title":"Antiviral effect of ribavirin against HCV associated with increased frequency of G-to-A and C-to-U transitions in infectious cell culture model","volume":"8","author":"Galli","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2019.09.014_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2019.09.014_bib15","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","article-title":"Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a\/2a (S52\/JFH1) viruses","volume":"133","author":"Gottwein","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib16","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1128\/JVI.00049-11","article-title":"Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A","volume":"85","author":"Gottwein","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1440-1746.2005.04024.x","article-title":"Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy","volume":"20","author":"Hamano","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virol.2019.09.014_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2334-11-177","article-title":"Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study","volume":"11","author":"Hansen","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.virol.2019.09.014_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.21932","article-title":"Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial","volume":"46","author":"Jacobson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2019.09.014_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/17476348.2017.1338567","article-title":"Respiratory syncytial virus: prospects for new and emerging therapeutics","volume":"11","author":"Jorquera","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.virol.2019.09.014_bib23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2019.09.014_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.08.007","article-title":"Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice","volume":"146","author":"Kamiyama","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2019.09.014_bib25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/AAC.02436-15","article-title":"A complex network of interactions between S282 and G283 of hepatitis C virus nonstructural protein 5B and the template strand affects susceptibility to sofosbuvir and ribavirin","volume":"60","author":"Kulkarni","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2019.09.014_bib26","first-page":"E1101","article-title":"Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2019.09.014_bib27","doi-asserted-by":"crossref","first-page":"19757","DOI":"10.1073\/pnas.1218260109","article-title":"Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2019.09.014_bib28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2013.11.009","article-title":"Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JVI.02877-14","article-title":"Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77","volume":"89","author":"Li","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.virol.2019.09.014_bib31","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1053\/j.gastro.2007.03.035","article-title":"Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy","volume":"132","author":"Lutchman","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib32","doi-asserted-by":"crossref","first-page":"46094","DOI":"10.1074\/jbc.C100349200","article-title":"Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin","volume":"276","author":"Maag","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2019.09.014_bib33","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.virol.2019.09.014_bib34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1099\/jgv.0.001095","article-title":"Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a","volume":"99","author":"Mejer","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","article-title":"Antiviral action of ribavirin in chronic hepatitis C","volume":"126","author":"Pawlotsky","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib36","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2019.09.014_bib37","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/JVI.79.4.2346-2355.2005","article-title":"Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA","volume":"79","author":"Pfeiffer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.virol.2019.09.014_bib39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2019.09.014_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.antiviral.2018.07.014","article-title":"Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: essential tools in testing of antivirals and emerging vaccine strategies","volume":"158","author":"Ramirez","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2019.09.014_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.26660","article-title":"Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors","volume":"59","author":"Ramirez","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2019.09.014_bib42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib43","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2019.09.014_bib44","article-title":"Sofosbuvir and ribavirin therapy for children 3 to <12 Years old with hepatitis C virus genotype 2 or 3 infection","author":"Rosenthal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2019.09.014_bib45","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","article-title":"Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha","volume":"140","author":"Scheel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib46","doi-asserted-by":"crossref","first-page":"12098","DOI":"10.1128\/JVI.01860-14","article-title":"Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus","volume":"88","author":"Sheldon","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.virol.2019.09.014_bib48","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1099\/jgv.0.000612","article-title":"Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family","volume":"97","author":"Smith","year":"2016","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13401","article-title":"Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs","author":"Suda","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.virol.2019.09.014_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000095151","article-title":"Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon\/ribavirin combination therapy","volume":"49","author":"Sugihara","year":"2006","journal-title":"Intervirology"},{"key":"10.1016\/j.virol.2019.09.014_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jmv.20144","article-title":"Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy","volume":"74","author":"Vuillermoz","year":"2004","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virol.2019.09.014_bib52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2019.09.014_bib53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/apt.14354","article-title":"Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis","volume":"46","author":"Waldenstrom","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.virol.2019.09.014_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2893.2008.00980.x","article-title":"Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase","volume":"15","author":"Ward","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virol.2019.09.014_bib55","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2019.09.014_bib56","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.05.007","article-title":"Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir","author":"Wing","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2019.09.014_bib57","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2019.09.014_bib58","first-page":"869","article-title":"Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy","volume":"38","author":"Young","year":"2003","journal-title":"Hepatology"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268221930279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268221930279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:51:21Z","timestamp":1758588681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004268221930279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":58,"alternative-id":["S004268221930279X"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2019.09.014","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2019.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}